Latest PDE5 inhibitors Stories
MOUNTAIN VIEW, Calif., Nov. 18 /PRNewswire-FirstCall/ -- VIVUS, Inc.
MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m.
MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Lazard Capital Markets 6th Annual Healthcare Conference. The VIVUS presentation will take place at The St.
MOUNTAIN VIEW, Calif., Nov. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc.
SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED).
For patients with erectile dysfunction, treatment with oral medications demonstrates significant improvements in sexual intercourse and erectile function.
MOUNTAIN VIEW, Calif., Sept. 28 /PRNewswire-FirstCall/ -- VIVUS, Inc.
Compounds related to Viagra, which is already in clinical trials to prevent heart failure, may also counter the disease in a different way.
Scientists reported on Monday that they are in the process of developing a topical anti-impotence cream.
New drug delivery system could significantly lessen side effects.
- A volcanic mudflow.